Blog

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Blog

ArriVent and Alphamab Partner in $615.5 million collaboration for Novel ADC Cancer Treatments – GeneOnline

Collage of ArriVent and Alphamab

Jun 8, 2024, 06:47

ArriVent and Alphamab Partner in $615.5 million collaboration for Novel ADC Cancer Treatments – GeneOnline

GeneOnline shared a post on LinkedIn:

“ArriVent BioPharma and Alphamab Oncology announce a $615.5 million collaboration to develop and commercialize novel antibody-drug conjugates (ADCs) for cancer treatment. This partnership leverages cutting-edge ADC technology and global commercialization expertise.”

Further Reading.
Source: GeneOnline/LinkedIn

Alphamab Oncology Antibody drug conjugates ArriVent BioPharma cancer treatment Cnacer GeneOnline OncoDaily Oncology

Oct 22, 2024, 16:41

Naveen Pemmaraju: Delighted to have received my copy of The Cancer Journey by Chadi Nabhan

Oct 22, 2024, 16:37

Megan-Claire Chase: Bringing breast cancer education to the Black community

Oct 22, 2024, 16:31

The biology and the role of biomarkers in SCLC - LUNGevity Foundation

Oct 22, 2024, 16:29

Matthias Guckenberger: Honored to represent ESTRO at international meetings

Oct 22, 2024, 16:22

Join us for insights into radiotherapy for cutaneous lymphoma - EORTC

Oct 22, 2024, 16:16

Hedley Lewis: We must always listen for more as we continue to enhance our support for families navigating childhood cancer.

Oct 22, 2024, 16:07

Nelson Dusetti: Franco-Argentine Workshop on Pancreatic Cancer Research

Oct 22, 2024, 16:07

Fumiko Ladd Chino: Building instead of Fixing

Oct 22, 2024, 16:04

Jennifer Bires: The urgent issue of Health Literacy and its impact on equitable healthcare access and treatment

Oct 22, 2024, 16:00

Ann Partridge: 20th Young and Strong Forum for patients and families

Oct 22, 2024, 15:58

Registration for the 3rd annual TexasLung25 is LIVE - TLC Conference

Oct 22, 2024, 15:58

Anirban Maitra: Revolution Medicines has launched its phase 3 study of RMC-6236